ICML 2015

 
 
 

The 13th International Conference on Malignant Lymphoma took place June 17-20, 2015, in Lugano, Switzerland.

 

Novel mAb targeting CD70 shows activity in TCL

Erilyn Riley Read Article
Published: 07/08/15

monoclonal_antibodies_growing_Credit_Linda_Bartlett_230.jpg
Growing monoclonal antibodies
Photo by Linda Bartlett

The defucosylated monoclonal antibody (mAb) ARGX-110, which is active against CD70-bearing tumor cells and CD70-dependent stimulation of regulatory T cells, has shown activity in relapsed/refractory T-cell lymphoma (TCL), according to investigators. Of the 8 TCL patients enrolled in a phase 1 trial of ARGX-110, 3 had a biological response to the mAb. In this dose-escalation trial, the maximum tolerated dose of ARGX-110 was not reached. [Read Article]

Novel SYK inhibitor shows ‘good early evidence’ of activity

Erilyn Riley Read Article
Published: 07/05/15

dlbcl_wiki_240.jpg
Micrograph showing DLBCL

The phase 1, first-in-human study of the novel SYK inhibitor TAK-659 is showing “good early evidence” of antitumor activity in patients with lymphoma, according to investigators. The agent also appears to be fairly well tolerated, with 10 categories of adverse events occurring in 2 or more patients. Adam M. Petrich, MD, of Northwestern University in Evanston, Illinois, presented results from this ongoing study at the 13th International Congress on Malignant Lymphoma. [Read Article]

Team endorses intensified chemo for PET-positive HL

Erilyn Riley Read Article
Published: 06/30/15

young_adult_pt_receiving_chemo_Credit_Rhoda_Baer_230.jpg
Patient receives chemotherapy
Photo by Rhoda Baer

Long-awaited results of the Intergroup H10 trial in PET-positive Hodgkin lymphoma (HL) patients have shown that intensifying chemotherapy significantly increases 5-year progression-free survival (PFS) and produces a non-significant increase in overall survival (OS). Switching patients who are PET-positive after 2 cycles of ABVD to escalated BEACOPP and involved-node radiotherapy increased 5-year PFS to 91% and 5-year OS to 96%. [Read Article]

‘Radically different’ PI3Kδ inhibitor lacks hepatotoxicity

Erilyn Riley Read Article
Published: 06/30/15

oconnor-owen-tclf14-larry-young_230_brt.jpg
Owen O’Connor, MD, PhD
Photo by Larry Young

Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated with other PI3Kδ inhibitors. Investigators also confirmed that no case of colitis has been reported to date with TGR-1202, and only 2% of evaluable patients on this trial have experienced grade 3-4 diarrhea. The study is an ongoing, first-in-human trial in patients with relapsed or refractory hematologic malignancies. [Read Article]

Nivolumab produces ‘dramatic’ responses in HL

Erilyn Riley Read Article
Published: 06/25/15

timmerman-john-ucla-230.jpg
John Timmerman, MD
Photo courtesy of UCLA

The PD-1 checkpoint inhibitor nivolumab produces rapid, durable, and, in some cases, “dramatic” responses in Hodgkin lymphoma (HL), according to a speaker at the 13th International Congress on Malignant Lymphoma. The drug has also produced durable responses in follicular lymphoma (FL), cutaneous T-cell lymphoma (CTCL), and peripheral T-cell lymphoma (PTCL), although patient numbers for these malignancies are small. [Read Article]

Targeted agent shows early promise for NHL

HT Staff Read Article
Published: 06/25/15

follicular-lymphoma-230.jpg
Micrograph showing
follicular lymphoma

An anti-CD37 antibody-radionuclide conjugate provides sustained efficacy and a manageable safety profile in patients with relapsed, CD37+ non-Hodgkin lymphoma (NHL), according to researchers. The drug, 177Lu-DOTA-HH1 (Betalutin), consists of the tumor-specific antibody HH1, which targets the CD37 antigen on the surface of NHL cells, conjugated to the β-emitting isotope lutetium-177 (Lu-177) via the chemical linker DOTA. [Read Article]

Thiotepa, rituximab improve response in CNS lymphoma

Erilyn Riley Read Article
Published: 06/24/15

ICML_Palazzo_exterior_230.jpg
Palazzo Dei Congressi,
site of 13-ICML

Adding thiotepa and rituximab to the treatment of primary central nervous system (CNS) lymphoma is feasible from a safety perspective and has yielded promising results, according to new research. An analysis of the IELSG 32 trial—in which patients received methotrexate and cytarabine alone, with rituximab, or with rituximab and thiotepa—has shown the 4-drug regimen improves responses and progression-free survival. [Read Article]

EZH2 inhibitor proves active in rel/ref NHL

HT Staff Read Article
Published: 06/23/15

FL_cells_240.jpg
Micrograph showing FL

The EZH2 inhibitor tazemetostat (EPZ-6438) has shown “meaningful clinical activity” as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL), according to researchers. In a phase 1 trial, 9 of the 15 evaluable NHL patients achieved an objective response to tazemetostat. This included 2 ongoing complete responses (CRs), 1 in a patient with diffuse large B-cell lymphoma (DLBCL) and 1 in a patient with follicular lymphoma (FL). [Read Article]

Bleomycin can be safely omitted after negative PET2 in HL

Erilyn Riley Read Article
Published: 06/23/15

PET_scanner_Jens_Maus-230.jpg
PET scanner
Photo by Jens Maus

Results of the RATHL trial indicate that bleomycin can be omitted from ABVD therapy following a negative interim FDG-PET scan in patients with Hodgkin lymphoma. Progression-free survival (PFS) and overall survival (OS) were the same at 3 years for patients who were PET-negative after 2 cycles of ABVD and then continued therapy with or without bleomycin. These results were presented at the 13th International Conference on Malignant Lymphoma. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}